SSSimon Sanderson

Simon Sanderson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Simon Sanderson has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • A Green

    West Midlands Laboratory Service for Inherited Metabolic Disorders, Birmingham Children’s Hospital, Birmingham, UK

    1 shared publication
  • Ann-Louise Kinmonth

    From University of Cambridge, Addenbrooke's Hospital, and Institute of Public Health, Cambridge, United Kingdom; and University of Western Australia, Claremont, Western Australia, Australia

    1 shared publication
  • David Melzer

    Emeritus Professor (retired), University of Exeter, St Luke’s Campus, Exeter, UK

    1 shared publication
  • Graham Shortland

    University Hospital of Wales

    1 shared publication
  • H Burton

    Public Health Genetics Unit, Cambridge, UK

    1 shared publication
  • Hilary Burton

    Public Health Genetics Unit, Cambridge, UK

    1 shared publication

Latest Publications

    • 1 January 2007
      • Vol. 62  (4) , 831-48

    Closing the gaps--enhancing the regulation of genetic tests using responsive regulation.

    by Stuart Hogarth, Kathy Liddell, Tom Ling, Simon Sanderson, Ron Zimmern, David Melzer

  • The incidence of inherited metabolic disorders in the West Midlands, UK

    by S Sanderson, A Green, M A Preece, H Burton

    Background: Inherited metabolic disorders (IMDs) are a heterogeneous group of genetic conditions mostly occurring in childhood. They are individually rare but collectively numerous, causing substantial morbidity and mortality. Aims: To obtain up-to-date estimates of the birth prevalence of IMDs in an ethnically diverse British population and to compare these estimates with those of other published population-based studies. Methods: Retrospective data from the West Midlands Regional Diagnostic Laboratory for Inherited Metabolic Disorders (Birmingham, UK) for the 5 years (1999–2003) were examined. The West Midlands population of 5.2 million is approximately 10% of the UK population. Approximately 11% of the population of the region is from black and ethnic minority groups compared with approximately 8% for the the UK. Results: The overall birth prevalence was 1 in 784 live births (95% confidence interval (CI) 619 to 970), based on a total of 396 new cases. The most frequent diagnoses were mitochondrial disorders (1 in 4929; 95% CI 2776 to 8953), lysosomal storage disorders (1 in 5175; 95% CI 2874 to 9551), amino acid disorders excluding phenylketonuria (1 in 5354; 95% CI 2943 to 9990) and organic acid disorders (1 in 7962; 95% CI 3837 to 17 301). Most of the diagnoses (72%) were made by the age of 15 years and one-third by the age of 1 year. Conclusions: These results are similar to those of the comparison studies, although the overall birth prevalence is higher in this study. This is probably due to the effects of ethnicity and consanguinity and increasing ascertainment. This study provides useful epidemiological information for those planning and providing services for patients with IMDs, including newborn screening, in the UK and similar populations.


  • Needs assessment and review of services for people with inherited metabolic disease in the United Kingdom

    by Hilary Burton, Simon Sanderson, Graham Shortland, Philip Lee

    Patients with inherited metabolic diseases need to be viewed as a specialist care group because of the range of expertise required for their diagnosis and management. In the UK, professional concerns have been expressed that existing services would struggle to meet needs resulting from new diagnostic and screening techniques, new treatments and increased survival. This needs assessment and service review was therefore undertaken at the request of the Joint Committee on Medical Genetics, guided by a national multidisciplinary stakeholder group. All 24 specialist centres identified in the UK provided evidence for the review. Approximately 10 000 patients are known to services and their annual number of referrals is increasing. Possible shortfalls in the number of patients attending specialist services were estimated for the UK as a whole by extrapolating the results from the region with the most comprehensive service and comparing this with known patient numbers. This analysis suggests that a further 5600 children and 3300 adults are not looked after by specialist services or have been lost to follow-up. The comprehensiveness of services was assessed using a new scoring system for clinical and organizational criteria. There are major regional disparities in the comprehensiveness of service provision across the country, with some regions having little or no specialist service. Unmet need will increase as a result of new diagnostic technologies, more effective treatments and new neonatal screening programmes; specialist services need to be developed and expanded to provide a comprehensive and more equitable service to the UK population.


  • Narrative Review: Aspirin Resistance and Its Clinical Implications

    by Simon Sanderson, Jon Emery, Trevor Baglin, Ann-Louise Kinmonth

    Aspirin is currently the most cost-effective drug for the secondary prevention of cardiovascular disease, but treatment failures are relatively common. Several factors have been linked to these recurrent vascular events in patients prescribed aspirin, including smoking, drug interactions, nonadherence, comorbid conditions, and aspirin resistance. The term aspirin resistance has been used to describe not only an absence of the expected pharmacologic effects of aspirin on platelets but also poor clinical outcomes, such as recurrent vascular events, in patients treated with aspirin. Aspirin resistance is perhaps more precisely understood as the phenomenon of measurable, persisting platelet activation that occurs in patients prescribed a therapeutic dose of aspirin and may underlie an unknown proportion of aspirin treatment failures. Key challenges for future research are to standardize a definition of aspirin resistance and to compare whether different measures of platelet activation, either alone or in combination, independently predict cardiovascular events. These challenges must be met before researchers conduct studies to assess the clinical utility of testing on patient outcomes and cost-effective prescribing.